Abstract 30P
Background
Oral squamous cell carcinoma (OSCC) represents one of the six most common cancers in the world. The identification of new prognostic markers could help clinicians explore the biological characteristics of OSCC and develop more personalized treatment plans for patients based on their risk factors. The discovery and study of new prognostic markers of OSCC may help improve treatment outcomes through more accurate and effective treatment strategies, ultimately leading to improved survival and quality of life in patients with OSCC. The aim of this study was to identify the prognostic value of CDKN2A and miRNAs, involved in its regulation as markers of OSCC.
Methods
In the present study we have results of the examination and treatment of 70 patients with stage II–IV OSCC. miR-10b and -155 and mRNA of CDKN2A in tumor samples of patients with OSCC was analyzed by real-time reverse transcription polymerase chain reaction. Detection of p16INK4a was performed by simultaneous immunohistochemical assessment in tumor cells.
Results
We found a strong correlation of studied miRNAs expression with lymph node metastasis (r=0.56 for miR-10b and 0.59 for miR-155). Also, there is no differences in miR-10b and -155 between p16INK4a+ and p16INK4a- samples. p16INK4a status does not affect the association of both miRNAs with lymph node metastases.
Conclusions
The results indicate the relation between miR-10b and -155 and the presence of lymph node metastases of patients with OSCC and thus they can be used as prognostic markers of the disease.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract